Irinotecan/Capecitabine Versus Capecitabine in Patients Treated With A/T for HER2 Negative Metastatic Breast Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2011
This study is a multicenter, randomized study, open-label, phase III study.The efficacy of irinotecan and capecitabine combination will be superior to capecitabine alone in term of progression free survival in metastatic breast cancer patients previously treated with anthracycline and taxane.
Epistemonikos ID: adeb5ec38668a0559779fe369ff7ff584c175126
First added on: May 10, 2024